CBA-1205
Model: Antibody Drug Candidate
Category: Pharmaceutical
Exhibitor: CHIOME BIOSCIENCE INC.
Booth No: N1107
Characteristic
”CBA-1205” :Phase I
・A first-in-class antibody drug candidate targeting the DLK-1 tumor antigen
・Clinical studies for hepatocellular carcinoma and melanoma are ongoing.
・The antibody has enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) through modification of the Fc glycan structure.
・The substance patent is registered in Japan, the US, EU, China and other countries.
Other Products
Products you may be interested in
Highest Rated Products